查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1383726

咽炎治疗市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按疾病类型、药物类别、配销通路、地区和竞争细分

Pharyngitis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Disease Type, By Drug Class, By Distribution Channel By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 174 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022 年全球咽炎治疗市场价值为 21 亿美元，预计在预测期内将强劲增长，到 2028 年复合CAGR为4.42%。全球咽炎治疗市场是医疗保健行业中一个充满活力且不断发展的领域，重点在于解决咽炎的诊断、管理和治疗问题，咽炎是一种以咽部发炎为特征的常见疾病，通常会导致喉咙痛。近年来，在几个关键因素的推动下，该市场见证了显着的成长和创新。

首先，咽炎在世界各地的盛行率仍然很高，病毒和细菌感染都会导致这种情况。这导致对有效治疗方案的需求不断增长，包括药物、非处方药和非药物干预措施。因此，製药公司一直在积极开发新的药物和疗法，以缓解咽炎的症状和根本原因。

此外，技术进步以及远距医疗和数位健康解决方案的日益采用已经改变了全球医疗保健格局。这些创新促进了咽炎的更好诊断和远端监测，为患者提供了更方便、更容易获得的护理选择。此外，COVID-19 大流行凸显了远距医疗在管理包括咽炎在内的呼吸道疾病的重要性。市场也反映出人们对预防措施越来越感兴趣，因为医疗保健提供者和患者都认识到最大限度降低咽炎復发风险的价值。这导致了一些导致咽炎的关键病原体（例如化脓性链球菌）的疫苗的开发。

市场概况
预测期 2024-2028
2022 年市场规模 21亿美元
2028 年市场规模 27亿美元
2023-2028 年CAGR 4.42%
成长最快的细分市场 网路药局
最大的市场 北美洲

此外，人们对抗生素抗药性的认识不断增强，这导致了治疗方法的转变。医疗保健专业人员对抗生素的过度使用越来越谨慎，并正在探索治疗咽炎病例的替代疗法和指南。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：全球咽喉炎治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依疾病类型（急性咽炎、慢性咽喉炎）
    • 依药物类别（抗生素、抗病毒药物、皮质类固醇、抗霉菌药物、其他）
    • 按配销通路（医院药房、零售药房、网路药房）
    • 按地区
    • 按公司划分 (2022)
  • 市场地图
    • 依疾病类型
    • 按药物类别
    • 按配销通路
    • 按地区

第 5 章：亚太地区咽喉炎治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依疾病类型
    • 按药物类别
    • 按配销通路
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国咽喉炎治疗
    • 印度咽喉炎治疗
    • 澳洲咽炎治疗
    • 日本咽喉炎治疗
    • 韩国咽喉炎治疗

第 6 章：欧洲咽喉炎治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依疾病类型
    • 按药物类别
    • 按配销通路
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 西班牙
    • 义大利
    • 英国

第 7 章：北美咽喉炎治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依疾病类型
    • 按药物类别
    • 按配销通路
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 8 章：南美洲咽喉炎治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依疾病类型
    • 按药物类别
    • 按配销通路
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 9 章：中东和非洲咽炎治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依疾病类型
    • 按药物类别
    • 按配销通路
    • 按国家/地区
  • MEA：国家分析
    • 南非咽喉炎治疗
    • 沙乌地阿拉伯咽喉炎治疗
    • 阿联酋咽炎治疗
    • 埃及咽喉炎治疗

第 10 章：市场动态

  • 司机
  • 挑战

第 11 章：市场趋势与发展

  • 最近的发展
  • 产品发布
  • 併购

第 12 章：全球咽炎治疗市场：SWOT 分析

第 13 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第14章：竞争格局

  • 辉瑞公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Current Capacity Analysis
    • Financials (In case of listed)
    • Recent Developments
    • SWOT Analysis
  • 诺华公司
  • Amneal 製药股份有限公司
  • 肯维公司
  • 桑顿罗斯有限公司
  • 利洁时集团有限公司
  • 霍尼部
  • 威望消费者保健公司
  • 传统医药公司
  • 罗森製药列兵。有限公司

第 15 章：策略建议

第 16 章：关于我们与免责声明

简介目录
Product Code: 17540

Global Pharyngitis Treatment Market has valued at USD 2.10 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 4.42% through 2028. The Global Pharyngitis Treatment Market is a dynamic and evolving sector within the healthcare industry that focuses on addressing the diagnosis, management, and treatment of pharyngitis, a common medical condition characterized by inflammation of the pharynx, typically resulting in a sore throat. This market has witnessed significant growth and innovation in recent years, driven by several key factors.

First and foremost, the prevalence of pharyngitis remains high worldwide, with both viral and bacterial infections contributing to the condition. This has led to a growing demand for effective treatment options, including pharmaceuticals, over-the-counter remedies, and non-pharmacological interventions. As a result, pharmaceutical companies have been actively developing new drugs and therapies to alleviate the symptoms and underlying causes of pharyngitis.

Furthermore, the global healthcare landscape has been transformed by technological advancements and the increasing adoption of telemedicine and digital health solutions. These innovations have facilitated better diagnosis and remote monitoring of pharyngitis, offering patients more convenient and accessible care options. In addition, the COVID-19 pandemic has underscored the importance of telehealth in managing respiratory conditions, including pharyngitis. The market also reflects a growing interest in preventive measures, as healthcare providers and patients alike recognize the value of minimizing the risk of recurrent pharyngitis episodes. This has led to the development of vaccines targeting some of the key pathogens responsible for pharyngitis, such as Streptococcus pyogenes.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 2.10 Billion
Market Size 2028USD 2.70 Billion
CAGR 2023-20284.42%
Fastest Growing SegmentOnline Pharmacies
Largest MarketNorth America

Moreover, there is a heightened awareness of antibiotic resistance, which has led to a shift in treatment approaches. Healthcare professionals are increasingly cautious about antibiotic overuse and are exploring alternative therapies and guidelines for managing pharyngitis cases.

Key Market Drivers

Technological Advancements

Technological advancements are playing a pivotal role in propelling the growth of the Global Pharyngitis Treatment Market. In recent years, the healthcare industry has witnessed a remarkable transformation in the way pharyngitis, commonly known as a sore throat, is diagnosed, managed, and treated. These advancements have not only improved patient care but also enhanced the efficiency and effectiveness of healthcare systems worldwide.

Telemedicine and digital health solutions have emerged as significant drivers of change in the pharyngitis treatment landscape. These innovations have facilitated remote consultations and monitoring, allowing healthcare providers to offer timely care while minimizing patient inconvenience and the risk of disease transmission, particularly in the context of the COVID-19 pandemic. Patients can now seek medical advice and receive treatment for pharyngitis from the comfort of their homes, marking a paradigm shift in healthcare accessibility.

Advancements in diagnostic tools and techniques have revolutionized the identification of pharyngitis causes. Molecular diagnostics and rapid testing methods enable healthcare professionals to differentiate between viral and bacterial infections swiftly and accurately. This differentiation is critical, as it guides treatment decisions, reducing the unnecessary prescription of antibiotics, which in turn addresses the global concern of antibiotic resistance. These technologies not only improve patient outcomes but also contribute to responsible antibiotic use.

Artificial intelligence (AI) and machine learning algorithms have also found applications in pharyngitis treatment. These technologies analyze vast datasets to identify patterns, enabling earlier and more accurate diagnoses of pharyngitis and its underlying causes. They can assist healthcare providers in predicting disease progression and tailoring treatment plans to individual patient needs, ultimately improving treatment outcomes and reducing healthcare costs.

Furthermore, telehealth platforms and mobile applications have empowered patients to actively participate in their healthcare management. Patients can access information about pharyngitis, receive medication reminders, and monitor their symptoms, leading to better treatment adherence and outcomes. These digital tools also facilitate communication between patients and healthcare providers, fostering a collaborative approach to managing pharyngitis..

Changing Treatment Approaches

Changing treatment approaches have played a pivotal role in driving growth within the Global Pharyngitis Treatment Market. Traditionally, the treatment of pharyngitis, or sore throat, often involved a one-size-fits-all approach that relied heavily on antibiotics. However, evolving clinical practices and medical guidelines have brought about a paradigm shift in the way pharyngitis is managed, leading to a more targeted and patient-centric approach.

One of the key drivers of change has been a growing concern about antibiotic resistance. The overuse and misuse of antibiotics have contributed to the emergence of antibiotic-resistant strains of bacteria, posing a significant public health threat. In response, healthcare authorities and professionals have revised treatment guidelines, emphasizing the importance of evidence-based care. Antibiotics are now recommended primarily for cases where bacterial infections, particularly Group A Streptococcus, are confirmed through diagnostic tests. This approach not only preserves the efficacy of antibiotics but also reduces the risk of adverse reactions and complications associated with their use.

Furthermore, changing treatment approaches have emphasized the importance of symptom management and patient comfort. Pharyngitis can be caused by viral infections that do not respond to antibiotics, leading to the development of non-pharmacological interventions and over-the-counter remedies aimed at relieving symptoms such as pain and inflammation. These treatments offer patients relief while minimizing the potential side effects of antibiotics.

Patient education has also played a critical role in changing treatment approaches. Healthcare providers are now better equipped to educate patients about the nature of pharyngitis, the importance of completing prescribed treatments, and recognizing warning signs of complications. Patients are increasingly encouraged to seek medical attention for persistent or severe sore throats, resulting in earlier diagnosis and more effective treatment. In conclusion, the changing treatment approaches within the Global Pharyngitis Treatment Market represent a significant driver of growth. The shift towards evidence-based care, the responsible use of antibiotics, and the emphasis on symptom management and patient education have collectively improved the quality of care for individuals with pharyngitis.

Increased Healthcare Awareness

The Global Pharyngitis Treatment Market has been positively impacted by increased healthcare awareness, as heightened awareness has led to a greater understanding of the importance of timely diagnosis and treatment of pharyngitis, commonly referred to as a sore throat. Healthcare awareness initiatives have played a pivotal role in educating both healthcare professionals and the general public about the risks, complications, and appropriate management of this prevalent condition.

One of the significant outcomes of increased healthcare awareness is early detection. Patients are now more likely to seek medical attention for persistent or severe sore throats, which can be indicative of various underlying causes, including bacterial infections like Group A Streptococcus. This early diagnosis enables healthcare providers to initiate appropriate treatment promptly, reducing the duration and severity of symptoms and minimizing the risk of complications.

Additionally, healthcare awareness campaigns have emphasized the importance of completing prescribed treatments. Patients are now more informed about the necessity of finishing a full course of antibiotics, especially when bacterial pharyngitis is confirmed through diagnostic tests. This adherence to treatment regimens not only improves individual patient outcomes but also contributes to the overall effectiveness of pharyngitis treatment, reducing the likelihood of antibiotic resistance development.

Healthcare professionals have also benefited from increased awareness, leading to more proactive and evidence-based management of pharyngitis cases. With a better understanding of the potential complications associated with untreated or inadequately managed pharyngitis, healthcare providers are more vigilant in their approach to diagnosis and treatment. This proactive stance ensures that patients receive appropriate care and, if necessary, are monitored for potential complications, such as rheumatic fever or acute glomerulonephritis.

Furthermore, healthcare awareness initiatives have fostered a culture of responsible antibiotic use. Patients and healthcare providers alike are more cognizant of the consequences of antibiotic overuse and misuse. This awareness has led to a more selective use of antibiotics, preserving their effectiveness for cases where they are genuinely needed, such as confirmed bacterial pharyngitis.

Key Market Challenges

Misdiagnosis and Overdiagnosis

Misdiagnosis and overdiagnosis are significant challenges that hinder the Global Pharyngitis Treatment Market. Pharyngitis, commonly known as a sore throat, is a prevalent condition caused by various factors, including viral and bacterial infections, as well as non-infectious causes. The difficulty in accurately distinguishing between these underlying causes poses a substantial obstacle to effective treatment.

Misdiagnosis occurs when healthcare providers incorrectly identify the cause of pharyngitis. In many cases, patients with viral pharyngitis are prescribed antibiotics, which are only effective against bacterial infections. This inappropriate use of antibiotics contributes to antibiotic resistance, a global public health crisis. Antibiotic-resistant bacteria are increasingly common and can render once-effective treatments useless, leading to more severe illnesses and higher healthcare costs. On the flip side, overdiagnosis involves the unnecessary identification of a condition, often leading to unnecessary treatments. In the context of pharyngitis, overdiagnosis may result in the prescription of antibiotics for patients who do not have bacterial infections. This can lead to several issues, including unnecessary healthcare expenditures, potential side effects from antibiotics, and the development of antibiotic resistance.

One of the reasons for misdiagnosis and overdiagnosis is the clinical similarity of symptoms between viral and bacterial pharyngitis. Both types of pharyngitis often present with a sore throat, fever, and swollen lymph nodes, making it challenging for healthcare providers to distinguish between them based solely on clinical observations.

Antibiotic Resistance

Antibiotic resistance is a pressing challenge that significantly hinders the Global Pharyngitis Treatment Market. Pharyngitis, commonly known as a sore throat, is a prevalent condition often caused by bacterial infections, particularly Group A Streptococcus. Historically, antibiotics have been the go-to treatment for bacterial pharyngitis. However, the overuse and misuse of antibiotics have led to the emergence of antibiotic-resistant strains of bacteria, complicating the treatment landscape for this condition. Antibiotic-resistant strains of bacteria, including those causing pharyngitis, do not respond to conventional antibiotics. This means that patients with antibiotic-resistant infections may experience prolonged and more severe symptoms, leading to increased discomfort and healthcare costs.

Pharyngitis, if left untreated or inadequately managed due to antibiotic resistance, can lead to complications such as rheumatic fever and acute glomerulonephritis. These conditions can be serious and have long-term health consequences. Treating antibiotic-resistant infections often requires more expensive and extensive interventions, including hospitalization and intravenous antibiotics. This places a substantial financial burden on healthcare systems and patients.

As antibiotic resistance becomes more widespread, healthcare providers have fewer effective treatment options at their disposal. This limits their ability to combat pharyngitis and other bacterial infections, increasing the urgency of finding alternative solutions.

Key Market Trends

Telemedicine and Digital Health Solutions

Telemedicine and digital health solutions have emerged as powerful drivers in boosting the Global Pharyngitis Treatment Market. These technological advancements have transformed the way pharyngitis, commonly known as a sore throat, is diagnosed, managed, and treated, offering numerous benefits to both healthcare providers and patients.

First and foremost, telemedicine has significantly improved access to healthcare for individuals with pharyngitis. Patients can now connect with healthcare professionals remotely, facilitating timely consultations, especially during the ongoing COVID-19 pandemic, when minimizing in-person visits is essential to reduce the risk of virus transmission. Telehealth platforms enable patients to seek medical advice, receive diagnoses, and obtain prescriptions without leaving the comfort of their homes. This convenience has proven invaluable in improving healthcare accessibility and ensuring that individuals with pharyngitis receive the care they need promptly.

Moreover, digital health solutions, including mobile applications and online health portals, have revolutionized the patient experience in pharyngitis treatment. These platforms offer various features such as symptom tracking, medication reminders, and access to educational materials about pharyngitis. Patients can actively engage in their healthcare management by monitoring their symptoms and adhering to treatment regimens more effectively. This increased patient engagement can lead to better treatment outcomes and a more comprehensive understanding of pharyngitis and its management.

For healthcare providers, telemedicine and digital health solutions streamline the diagnostic and treatment processes. Healthcare professionals can conduct remote assessments, view patient medical histories, and even prescribe medications electronically. This efficiency not only improves the quality of care but also reduces administrative burdens and enhances overall healthcare productivity. Additionally, the integration of digital health solutions allows for more accurate and secure record-keeping, ensuring that patient information is readily accessible to authorized healthcare personnel. This leads to better coordination of care and a more holistic approach to pharyngitis treatment.

Rise in Preventive Measures

The Global Pharyngitis Treatment Market is witnessing a significant boost from the rise in preventive measures. Pharyngitis, commonly known as a sore throat, is a widespread condition caused by various factors, including viral and bacterial infections. Preventive measures are increasingly becoming a proactive approach to reduce the incidence and severity of pharyngitis, thereby influencing the treatment landscape in several ways.

One of the key preventive measures in the fight against pharyngitis is the development and administration of vaccines. Vaccines targeting specific pathogens responsible for pharyngitis, such as Streptococcus pyogenes, are being researched and developed. These vaccines have the potential to substantially reduce the incidence of bacterial pharyngitis, particularly in high-risk populations like school-aged children. By preventing the initial infection, vaccines lessen the demand for antibiotic treatment, thereby reducing the burden on healthcare systems and contributing to the responsible use of antibiotics.

Furthermore, public health campaigns and education initiatives have played a vital role in promoting preventive measures for pharyngitis. These campaigns raise awareness about good hygiene practices, such as regular handwashing and covering one's mouth and nose when coughing or sneezing, to prevent the spread of viral and bacterial infections. By educating individuals about the importance of these basic preventive measures, the likelihood of infection transmission is reduced, leading to fewer cases of pharyngitis.

Moreover, preventive measures encompass the responsible use of antibiotics. As awareness of antibiotic resistance grows, healthcare providers are becoming more cautious about prescribing antibiotics for pharyngitis without confirmed bacterial infections. This shift toward evidence-based care and antibiotic stewardship programs aligns with global efforts to combat antibiotic resistance, ensuring that antibiotics remain effective for those who truly need them..

Segmental Insights

Disease Type Insights

Based on the Disease Type, the Acute Pharyngitis emerged as the dominant segment in the global market for Global Pharyngitis Treatment Market in 2022. Acute Pharyngitis is often caused by contagious pathogens like viruses (e.g., rhinovirus, adenovirus) and bacteria (e.g., Streptococcus pyogenes). The ease of transmission of these pathogens in communal settings like schools and workplaces contributes to the widespread prevalence of acute pharyngitis. This infectious nature leads to clusters of cases, which, in turn, drive up the demand for treatments to manage symptoms and prevent further transmission.

Acute Pharyngitis is often self-limiting, meaning that it tends to resolve on its own without the need for extensive medical intervention. While this can result in lower healthcare costs for mild cases, it still contributes to the overall prevalence of the condition.

Drug Class Insights

Based on the Drug Class, the Antibiotics segment emerged as the dominant player in the global market for Global Pharyngitis Treatment Market in 2022. Bacterial pharyngitis, if left untreated or inadequately managed, can lead to severe complications, such as rheumatic fever and acute glomerulonephritis. Antibiotics play a critical role in preventing these complications by eradicating the causative bacteria. This prevention aspect underscores the importance of antibiotics in the treatment of bacterial pharyngitis. Since antibiotics target and kill bacteria, they are the treatment of choice for bacterial infections like streptococcal pharyngitis. Healthcare providers often prescribe antibiotics when bacterial pharyngitis is confirmed through diagnostic tests, ensuring targeted and effective treatment.

Regional Insights

North America emerged as the dominant player in the global Pharyngitis Treatment Market in 2022, holding the largest market share. North America, particularly the United States, has one of the highest levels of healthcare spending in the world. This robust healthcare infrastructure ensures that a significant portion of the population has access to healthcare services, including diagnosis and treatment for pharyngitis. The availability of healthcare resources and funding contributes to the region's leadership in the pharyngitis treatment market. North America is at the forefront of medical advancements and technologies. This includes state-of-the-art diagnostic tools and treatment modalities for pharyngitis. Advanced diagnostic methods, such as PCR testing and rapid antigen tests, are widely available, enabling accurate and efficient diagnosis of pharyngitis causes, which in turn drives the demand for targeted treatments.

Key Market Players

Pfizer Inc

Novartis AG

Amneal Pharmaceuticals LLC

Kenvue Inc.

Thornton & Ross Ltd

Reckitt Benckiser Group Plc

Honibe

Prestige Consumer Healthcare Inc.

Traditional Medicinals, Inc.

Lozen Pharma Pvt. Ltd

Report Scope:

In this report, the Global Pharyngitis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Pharyngitis Treatment Market, By Disease Type:

  • Primary
  • Secondary
  • Tertiary

Global Pharyngitis Treatment Market, By Drug Class:

  • Glucocorticoid
  • Corticotropin
  • Others

Global Pharyngitis Treatment Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global Pharyngitis Treatment Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Pharyngitis Treatment Market.

Available Customizations:

  • Global Pharyngitis Treatment Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Pharyngitis Treatment Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Disease Type (Acute Pharyngitis, Chronic Pharyngitis)
    • 4.2.2. By Drug Class (Antibiotics, Antiviral Drugs, Corticosteroids, Antifungals, Others)
    • 4.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 4.2.4. By Region
    • 4.2.5. By Company (2022)
  • 4.3. Market Map
    • 4.3.1. By Disease Type
    • 4.3.2. By Drug Class
    • 4.3.3. By Distribution Channel
    • 4.3.4. By Region

5. Asia Pacific Pharyngitis Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Type
    • 5.2.2. By Drug Class
    • 5.2.3. By Distribution Channel
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Pharyngitis Treatment Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Disease Type
        • 5.3.1.2.2. By Drug Class
        • 5.3.1.2.3. By Distribution Channel
    • 5.3.2. India Pharyngitis Treatment Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Disease Type
        • 5.3.2.2.2. By Drug Class
        • 5.3.2.2.3. By Distribution Channel
    • 5.3.3. Australia Pharyngitis Treatment Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Disease Type
        • 5.3.3.2.2. By Drug Class
        • 5.3.3.2.3. By Distribution Channel
    • 5.3.4. Japan Pharyngitis Treatment Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Disease Type
        • 5.3.4.2.2. By Drug Class
        • 5.3.4.2.3. By Distribution Channel
    • 5.3.5. South Korea Pharyngitis Treatment Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Disease Type
        • 5.3.5.2.2. By Drug Class
        • 5.3.5.2.3. By Distribution Channel

6. Europe Pharyngitis Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type
    • 6.2.2. By Drug Class
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Pharyngitis Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Type
        • 6.3.1.2.2. By Drug Class
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Germany Pharyngitis Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Type
        • 6.3.2.2.2. By Drug Class
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Spain Pharyngitis Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Type
        • 6.3.3.2.2. By Drug Class
        • 6.3.3.2.3. By Distribution Channel
    • 6.3.4. Italy Pharyngitis Treatment Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Disease Type
        • 6.3.4.2.2. By Drug Class
        • 6.3.4.2.3. By Distribution Channel
    • 6.3.5. United Kingdom Pharyngitis Treatment Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Disease Type
        • 6.3.5.2.2. By Drug Class
        • 6.3.5.2.3. By Distribution Channel

7. North America Pharyngitis Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type
    • 7.2.2. By Drug Class
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Pharyngitis Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Drug Class
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Mexico Pharyngitis Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Drug Class
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Canada Pharyngitis Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Drug Class
        • 7.3.3.2.3. By Distribution Channel

8. South America Pharyngitis Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type
    • 8.2.2. By Drug Class
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Pharyngitis Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Drug Class
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Argentina Pharyngitis Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Drug Class
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Colombia Pharyngitis Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By Drug Class
        • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Pharyngitis Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type
    • 9.2.2. By Drug Class
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Pharyngitis Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Drug Class
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Saudi Arabia Pharyngitis Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Drug Class
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. UAE Pharyngitis Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Drug Class
        • 9.3.3.2.3. By Distribution Channel
    • 9.3.4. Egypt Pharyngitis Treatment Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Disease Type
        • 9.3.4.2.2. By Drug Class
        • 9.3.4.2.3. By Distribution Channel

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Pharyngitis Treatment Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Pfizer Inc
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. Novartis AG
  • 14.3. Amneal Pharmaceuticals LLC
  • 14.4. Kenvue Inc.
  • 14.5. Thornton & Ross Ltd
  • 14.6. Reckitt Benckiser Group Plc
  • 14.7. Honibe
  • 14.8. Prestige Consumer Healthcare Inc.
  • 14.9. Traditional Medicinals, Inc.
  • 14.10. Lozen Pharma Pvt. Ltd

15. Strategic Recommendations

16. About Us & Disclaimer